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Abstract Atrial fibrillation (AF) is associated with an
increased risk of stroke. AF-related strokes cause greater
disability and mortality than those in patients without AF,
and are associated with a significant clinical and economic
burden in Mexico. Antithrombotic therapy reduces stroke
risk in patients with AF and is recommended for all
patients except those classified as having a low stroke risk.
However, its use is suboptimal all around the world; one
study showed that only 4 % of Mexican patients with AF
who presented with ischemic stroke were in the therapeutic
range for anticoagulation. Vitamin K antagonists (VKAs)
such as warfarin or acenocoumarin have long been the only
oral anticoagulants for stroke prevention in AF. Although
effective, VKAs have disadvantages, including the need for
regular coagulation monitoring and dose adjustment.
Interactions with numerous common medications and
foods contribute to the risk of serious bleeding and
thrombotic events in VKA-treated patients. Thus novel oral
anticoagulants (NOACs), more properly called direct oral
anticoagulants (DOACs), such as dabigatran etexilate,
rivaroxaban, apixaban, and edoxaban (not available in
Mexico), have been developed. These offer the conve-
nience of fixed-dose treatment without the need for moni-
toring, and have few drug or food interactions. Pivotal
phase III trials have demonstrated that these agents are at
least as effective as warfarin in preventing stroke and are
associated with a reduced risk of intracranial hemorrhage.
With apixaban approved in Mexico in April 2013,
clinicians now have the choice of three novel DOACs as
alternatives to warfarin. However, it is yet to be established
which of these agents should be the first choice, and
treatment decisions are likely to depend on the individual
patient’s characteristics.
Key Points
In Mexico, it is estimated that atrial fibrillation (AF)
affects 426,025 people aged[60 years.
Cerebrovascular disease is the third leading cause of
death in the country, with 31,999 deaths in 2013;
about 5333 of those can be attributed to AF-
associated stroke. The direct cost of managing AF
would be the equivalent of between US$0.7 and 1.89
billion a year. About 66,460 Mexicans with
undetected AF could be receiving prevention
therapy. If all people with AF were managed using
oral anticoagulants, the number of
preventable strokes would be approximately 1993,
and this would provide potential cost offsets.
Direct oral anticoagulants (apixaban, dabigatran and
rivaroxaban) have been widely used in Mexico since
2008 (since 2011, for stroke prophylaxis in patients
with AF) and have demonstrated at least comparable
effectiveness to that of vitamin K antagonists, with
superior safety and simpler management. These
agents may represent an opportunity for long-term
management to be undertaken in anticoagulation
clinics in the first level of health care, by trained
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1 Introduction
Atrial fibrillation (AF), the most common type of sustained
cardiac arrhythmia, involves chaotic electrical activity in
the atria that leads to rapid, irregular ventricular contrac-
tion [1]. In Mexico, there are no available direct statistics
on the prevalence of AF, but the following calculations can
be made based on data published in the Mexican General
Census of Population and Housing 2010 [2] and data on AF
prevalence and mortality worldwide. The prevalence of AF
in the general population is estimated to be 1–2 % [3–5].
As the total population of Mexico in 2013 was 122,300,000
[2], this suggests that the prevalence of AF in Mexico is
between 1,223,000 and 2,446,000. This figure is very high,
probably because of the age structure of the Mexican
population, so a more believable figure is one adjusted for
age; the prevalence of AF increases with age, and AF in
older individuals is predominantly nonvalvular. An esti-
mated 3.8 % of individuals aged[60 years have AF [5]. In
Mexico, there are 11,211,186 people aged [60 years;
therefore, it can be estimated that 426,025 people in this
age group will have AF. Similarly, the prevalence of AF
among people aged[80 years has been estimated to be as
high as 15 % [3, 5, 6]. Thus, with 1,662,432 people in this
age group in Mexico, as many as 249,365 could have AF.
AF is associated with increased morbidity and mortality
due to complications including heart failure, systemic
embolism and stroke, and results in an impaired quality of
life [1, 3]. Patients with nonvalvular AF have a fivefold
increase in the risk of stroke, and one in every five strokes
is attributable to AF [3]. In addition to the higher incidence
of stroke among patients with AF versus the general pop-
ulation, strokes associated with AF are often more severe
and debilitating than other strokes, and are associated with
higher rates of disability and mortality [7]. In Mexico in
2013, cerebrovascular disease was the third leading cause
of death, with 31,999 deaths. It can be calculated that
approximately 5333 of these deaths (one in six) were due to
AF-associated stroke. This estimate is consistent with a
study that found AF in 15.2 % of the 7669 patients hos-
pitalized for first stroke in 2005 at five hospitals in Mexico
City [8]. In the PREMIER registry (Mexican First Record
Cerebral Ischemia), which included 1376 patients, mech-
anisms of cerebral ischemia were classified as undeter-
mined (41 %), cardioembolism (20 %), small vessel
disease (20 %), large vessel disease (8 %) and various
mechanisms (5 %); the frequency of AF among patients
with stroke or transient ischemic attack (TIA) in this reg-
istry was 10 % [9]. In a combined analysis of three Mex-
ican records with a total of 3194 patients with stroke or
TIA, the frequency of AF was 12.5 % among patients with
stroke and 8.1 % in patients with TIA [10]. The direct cost
of managing AF was calculated to be 0.9–2.4 % of the total
National Health Service (NHS) budget in the UK in 2000
[11]. In Mexico in 2014, the total health expenditure was
US$78.82 billion, so, assuming a similar proportion of the
total budget, we can calculate that the direct cost of
managing AF would be the equivalent of between US$0.7
and 1.89 billion a year. On the other hand, in Mexico,
426,025 people aged [60 years will have AF. If we
assume, conservatively, that about 24 % have undetected
AF and 35 % of these will have irreversible contraindica-
tions for warfarin [12], then about 66,460 Mexicans with
undetected AF could be receiving prevention therapy. If all
of these people were managed using oral anticoagulants,
the number of preventable strokes would be approximately
1993, and this would provide potential opportunity cost
offsets (in averted lifetime costs from first-ever ischemic
stroke events), taking into account that the risk of stroke in
patients with AF can be significantly reduced with appro-
priate use of antithrombotic medications, which is recom-
mended for all patients except those with the lowest risk
[1]. This review aims to describe the available pharmaco-
logical options for the prevention of stroke in patients with
AF in Mexico and the challenges associated with these
treatments, with a focus on the newly available direct oral
anticoagulants (DOACs).
2 Anticoagulants in Stroke Prevention
Oral antithrombotic agents, in particular anticoagulants, are
effective in reducing the risk of stroke in patients with AF
[3]. Anticoagulants inhibit blood clotting via one or more
steps in the coagulation cascade, and include oral vitamin
K antagonists (VKAs), direct thrombin inhibitors, direct
factor Xa inhibitors, and parenteral agents [unfractionated
and low-molecular-weight heparins (LMWHs), direct
thrombin inhibitors, and the indirect factor Xa inhibitor
fondaparinux]. Because primarily oral anticoagulants are
used in stroke prevention in AF, this review will focus on
these agents. VKAs have long been the mainstay of stroke
prevention in AF. VKAs inhibit coagulation by inhibiting
the recycling of vitamin K epoxide back to the active
reduced form of vitamin K [13]. Treatment with VKAs has
been shown to reduce the relative risk (RR) of stroke or
systemic embolism compared with control or placebo by
64 % [95 % confidence interval (CI) 49–74], with an
absolute RR of 2.7 % per year (number needed to treat, 37)
for embolism in patients with no history of prior stroke,
8.4 % per year (number needed to treat, 12) for patients
with a history of prior stroke, and 26 % (95 % CI 3–43 %;
absolute RR 1.6 % per year) for all-cause mortality [14].
Aspirin, an antiplatelet agent, has also been shown to
reduce the risk of stroke in patients with AF. A 42 % RR
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reduction was seen with aspirin 325 mg/day versus placebo
in the Stroke Prevention in AF (SPAF)-I study [15].
However, a meta-analysis of studies in which aspirin doses
ranged from 50 to 1300 mg/day showed only a non-
significant 19 % reduction in the incidence of first stroke
versus placebo [14]. Furthermore, meta-analysis of studies
directly comparing VKAs and aspirin showed VKAs to be
significantly more effective (38 % RR reduction) [14].
Dual antiplatelet therapy with aspirin plus clopidogrel has
also been evaluated for stroke prevention in AF. Atrial
Fibrillation Clopidogrel Trial with Irbesartan for Preven-
tion of Vascular Events (ACTIVE-W) found warfarin to be
more effective (40 % relative stroke risk reduction), and
while Atrial Fibrillation Clopidogrel Trial with Irbesartan
for Prevention of Vascular Events (ACTIVE-A) demon-
strated that aspirin plus clopidogrel was significantly more
effective than aspirin alone (28 % RR reduction), dual
antiplatelet therapy was associated with a significantly
higher incidence of major bleeding events [16, 17]. His-
torically, in Mexico the paradigm on the use of anticoag-
ulants for the prevention of stroke in patients with AF was
to determine ‘‘which patients require anticoagulation.’’
However, recently this paradigm has changed to the current
concept, or ‘‘Who are the real stroke low-risk patients, who
do not require anticoagulants?’’ (given their low absolute
risk for stroke). The 2012 European Guidelines for stroke
prevention in AF recommend the use of anticoagulants in
all patients except those classified as low risk (i.e., patients
who are\65 years of age and have no other cardiovascular
or concomitant disease), or without contraindications for
the use of these drugs [18–20]. The choice of anticoagu-
lation therapy should be based on individual patients’ RRs
of stroke/thromboembolism and bleeding and the net
clinical benefit (the balance between ischemic stroke pre-
vention and the potential risk of serial bleeding, in general
[1.5-fold) [18]. The risk of stroke in patients with AF is
not homogenous, and anticoagulants may not be warranted
in patients who do not have certain risk factors. To identify
low-risk patients, various thromboembolism/stroke risk
assessment tools have been developed [21]. The most
widely used are CHADS2 and CHA2DS2-VASc (Birm-
ingham 2009 schema) [21, 22]. The CHADS2 score esti-
mates patients’ stroke risk based on the presence of five
major risk factors (Table 1). However, it has only modest
predictive value (c-statistic of 0.58) and classifies most
patients as being ‘moderate-risk’ [3, 21]. Thus, while the
CHADS2 score is useful in the initial assessment of patients
with AF, use of a more detailed, risk factor-based tool,
CHA2DS2-VASc, is recommended when determining
which treatment (if any) should be prescribed [3]. In the
CHA2DS2-VASc score, vascular disease, age 65–74 years,
and female sex are incorporated into the original CHADS2
score (Table 1). An evaluation of CHA2DS2-VASc showed
that although the predictive value was only slightly higher
than that for CHADS2 (c-statistic of 0.606), patients were
less likely to be incorrectly classified as low risk [21].
All antithrombotic agents are associated with an
increased risk of bleeding events, including intracranial
hemorrhage (ICH) and other forms of major bleeding. In
some patients, the risk of bleeding associated with
antithrombotic therapy may outweigh the potential benefit
of treatment, despite these patients having an elevated risk
of ischemic stroke [23]. Bleeding risk in patients for whom
anticoagulant therapy is being considered may be assessed
using indices such as the HAS-BLED score [24]; however,
these tend to be less well validated than stroke risk scales
[23]. Risk factors for bleeding include hypertension, renal
and/or hepatic impairment, prior stroke, age [65 years,
low bodyweight, unstable or high international normalized
ratio (INR) values, concomitant medications (e.g., anti-
platelet agents, NSAIDs), and alcohol abuse [24]. Inter-
national practice guidelines recommend that patients with
at least one additional stroke risk factor (this includes
males with a CHA2DS2-VASc score of 1 and a score of 2
or higher for everyone else) receive oral anticoagulants,
either VKA with a target INR range of 2.0–3.0 or DOACs,
unless contraindicated [18–20]. The recommendations and
the use of the CHADS2 score and other risk factors in
determining the appropriate stroke prophylaxis for patients
with AF are summarized in the clinical flowchart shown in
Fig. 1. Recommendations regarding the use of DOACs will
be discussed later in this article.
2.1 Vitamin K Antagonists
The most commonly used VKAs are the coumarins; the
most prominent member of this class is warfarin. Warfarin






Cardiac failure 1 1
Hypertension 1 1
Age C75 years 1 2
Diabetes 1 1
Stroke or TIA 2 2
Vascular disease – 1
Age 65–74 years – 1
Sex category (female) – 1
Maximum score 6 9a
TIA transient ischemic attack
a Maximum score is 9, as the two age categories are mutually
exclusive
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inhibits the synthesis of the calcium-dependent clotting
factors II, VII, IX, and X, as well as the regulatory factors
protein C, protein S, and protein Z [13, 25]. Warfarin is
currently the most commonly used anticoagulant to prevent
stroke in patients with AF worldwide; however, aceno-
coumarin is widely used in Mexico, most other Latin
American countries, and Spain. VKAs are recommended
by evidence-based guidelines [3, 20, 26] as they have been
shown to be highly effective for reducing the risk of stroke
[27]. However, they have numerous disadvantages.
Because of its mechanism of action, warfarin has a slow
onset and offset of action [13]. Activated coagulation
factors produced before warfarin intake will continue to
function until degraded [13]. Furthermore, warfarin has a
long half-life (20–60 h), which leads to its slow offset of
action [13, 28]. In cases where reversal of anticoagulation
is required, the effects of warfarin can be reversed with
vitamin K; however, the onset of action of vitamin K is 6 h
and its maximal effect is 18–20 h. When rapid reversal is
needed, for example, in patients with major bleeding or
those requiring urgent surgery, prothrombin complex con-
centrate or fresh frozen plasma can be used [13]. Another
disadvantage of warfarin is its narrow therapeutic range
(target INR range usually 2.0–3.0 in patients with AF), and
that regular monitoring of the INR and dose adjustment are
required to ensure an adequate yet safe dose is taken [13].
An INR below the therapeutic target indicates that the dose
of warfarin is insufficient to protect against thromboem-
bolic events, whereas INRs exceeding the therapeutic range
increase the risk of major bleeding events [13]. Warfarin-
associated bleeding is among the most common causes of
drug-related morbidity and mortality and accounts for
33 % of reported adverse drug event-related hospitaliza-
tions, 71 % resulting from excessive doses [29]. While the
majority of patients enrolled in clinical trials of warfarin
remain in the INR range of 2.0–3.0, INR control is often
suboptimal in the ‘real world’ clinical practice setting, with
the average time spent in therapeutic range (TTR) ranging
from 56 % in retrospective studies to 65 % in randomized
controlled trials [30, 31]. Warfarin interacts with a large
number of commonly used medications and certain foods
(particularly leafy greens that contain large amounts of
vitamin K) [32]. Often, these interactions lead to INR
values being outside the appropriate therapeutic range [32].
Caution with concomitant medication use (including herbal
medicines) and diet is therefore necessary in patients
receiving warfarin.
2.2 Direct Oral Anticoagulant (DOACs)
In an effort to address the shortcomings of VKAs and to
improve patient outcomes, DOACs have been developed
that offer fixed-dose administration, have reduced potential
for drug and food interactions, and do not require routine
coagulation monitoring. These include the direct thrombin
inhibitor dabigatran etexilate and the direct factor Xa
inhibitors rivaroxaban, apixaban, and edoxaban, which are
marketed (edoxaban not marketed in Mexico), and agents
in late-stage clinical development, such as betrixaban
(Table 2). These DOACs have been studied, and in some
cases, they have received regulatory approval, in indica-
tions for which warfarin is used: stroke prevention in AF,
primary prevention of venous thromboembolism (VTE)
following orthopedic surgery, treatment and secondary
Fig. 1 Clinical flowchart for
the use of oral anticoagulation
for stroke prevention in AF
(Modified from the 2012 ESC
Guideline for the management
of atrial fibrillation [3], and
2014 Focused Update of the
Canadian Cardiovascular
Society Guidelines for the
Management of Atrial
Fibrillation [78]). AF atrial
fibrillation, bid twice daily,
DOAC direct oral anticoagulant,
GI gastrointestinal, INR
international normalized ratio,
TIA transient ischemic attack,
VKA vitamin K antagonist
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prevention of VTE, and in acute coronary syndrome
(ACS). The three DOACs that have been approved in
Mexico for stroke prevention in AF, dabigatran etexilate,
rivaroxaban, and apixaban, will be discussed further.
Advantages of the DOACs include their predictable phar-
macological effects, which allow fixed-dose administration
without the need for routine coagulation monitoring and
dose adjustment [33]. These agents also have a rapid onset
of effect and relatively short half-lives [28]. Furthermore,
they have reduced potential for interactions with drugs and
foods compared with warfarin [33]. However, these agents
also have certain drawbacks, such as the lack of standard
coagulation monitoring techniques; although coagulation
monitoring will not usually be necessary, it may be desir-
able in some cases, for example, in determining whether a
serious bleeding event is associated with excessive anti-
coagulation or when considering thrombolysis for patients
with acute thrombotic stroke [34].
Another relative disadvantage of the novel oral antico-
agulants is the potential need and current access to agents
that neutralize the action of DOACs. The short half-lives of
the novel anticoagulants should mean antidotes are not
necessary in many cases, although they may be desirable
in situations such as severe bleeding episodes or where
emergency surgery is required. It should be noted that
fondaparinux, low-molecular-weight heparin (LMWH)
have been used successfully for many years despite the
lack of antidotes for these agents [34].
Three molecules may provide an effective and safe way
of reversing the anticoagulant effects of DOACs:
1. Idarucizumab (Praxbind), a fragment of an antibody
(Fab), which is a specific antidote to the oral direct
thrombin inhibitor dabigatran, has been recently
approved in the USA by the Food and Drug Admin-
istration (FDA) and in Europe by the European
Medicines Agency (EMA). Interim results of 90
patients of the planned 300 from the RE-VERSal
Effects of Idarucizumab on Active Dabigatran Trial
(RE-VERSE AD) study [35] suggests that 5 g of
intravenous idarucizumab is safe and effective in
completely reversing the anticoagulant effect of dabi-
gatran within minutes in patients with AF who had
serious bleeding (51 patients) or required urgent
procedure (39 patients).
2. Andexanet alfa (r-Antidote, PRT064445; Portola Phar-
maceuticals) is a recombinant, modified truncated
form of enzymatically inactive factor Xa molecule,
which binds and reverses the anticoagulant action of
both the direct factor Xa inhibitors (e.g., rivaroxaban,
apixaban, and edoxaban) and the indirect Factor Xa
inhibitors (e.g., fondaparinux) [36]. Andexanet in older
healthy participants in the trials Andexanet Alfa a
Novel Antidote to the Anticoagulant Effects of fXA
Inhibitors–Apixaban Trial (ANNEXA-A) (48 partici-
pants randomly assigned to receive apixaban and 17
placebo) and Andexanet Alfa a Novel Antidote to the
Anticoagulant Effects of fXA Inhibitors–Rivaroxaban
Trial (ANNEXA-R) (53 patients randomly assigned to
receive rivaroxaban and 27 placebo) [37] reversed the
induced changes in anti-factor Xa activity and throm-
bin generation, and also reduced unbound factor Xa
inhibitor concentrations in apixaban- and rivaroxaban-
treated patients rapidly after an intravenous bolus,
sustaining that effect through a continuous infusion,
without evidence of clinical toxic effects or clinical
thrombosis.
3. Aripazine (PER-977, ciraparantag; Perosphere Inc.) is
an intravenously administered synthetic small mole-
cule (*500 Da) for use as a broad-spectrum reversal
agent for anticoagulants that reverses oral dabigatran,
apixaban, and rivaroxaban, and subcutaneous fonda-
parinux, unfractionated heparin (UFH) and LMWH
in vivo. It received fast-track status by the US FDA in
April 2015 as an investigational anticoagulant reversal
agent [38].
A high level of adherence is also important with the
DOACs, as each has a short-half life and their anticoagu-
lant effects will wear off after missing two or three doses,
Table 2 Direct oral anticoagulants in development for the prevention of stroke in atrial fibrillation worldwide
Drug Manufacturer Mechanism of
action
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whereas warfarin will maintain its anticoagulant effects for
considerably longer after the last dose [28]. Finally, all of
the direct anticoagulants have some degree of renal elim-
ination and their half lives are all increased in case of renal
impairment [39], meaning there is potential for drug
accumulation and hence increased bleeding risk in patients
with renal dysfunction; in particular, the use of dabigatran
etexilate requires that renal function is reviewed 2–3 times
per year [18]; in contrast, elimination of warfarin is entirely
hepatic [28].
2.2.1 Dabigatran Etexilate
Dabigatran etexilate (Pradaxa; Boehringer Ingelheim) is
an orally absorbed prodrug of dabigatran, a thrombin
inhibitor that has potent anticoagulant and antithrombotic
activity. Dabigatran etexilate competitively inhibits both
free and clot-bound thrombin, which is responsible for the
conversion of fibrinogen into fibrin (dabigatran etexilate is
rapidly converted by a serum esterase to dabigatran and has
an absolute bioavailability of 6.5 %) [40]. Dabigatran
etexilate has a serum half-life of 12–17 h, and 80 % of the
administered dose is excreted renally [40]. Dabigatran
etexilate is administered as a twice-daily oral dose that
does not require titration or coagulation monitoring. It has
been approved in 75 countries since 2008, including
Mexico, and is indicated for primary prevention of VTE
following major orthopedic surgery [41] and prevention of
stroke and systemic embolism in patients with nonvalvular
AF [42]. Dabigatran was approved by COFEPRIS, the
Mexican drug regulatory agency, for the prevention of
stroke and systemic embolism in patients with AF in June
2011 [43]. In Mexico, a 150-mg twice daily dosage is
indicated for all patients, except those with a potential risk
of major bleeding (e.g., those C75 years old), a CHADS2
score of C3, and/or previous gastrointestinal bleeding,
those receiving concomitant P-gp inhibitors, or those with
moderate renal impairment [creatinine clearance (CLCR)
30–50 mL/min], for whom the approved dose is 110 mg
twice daily [42]. Dabigatran etexilate is contraindicated in
patients with severe renal impairment (CLCR \30 mL/
min). Dabigatran etexilate has been recommended as an
alternative to warfarin for the prevention of stroke and
thrombosis in patients with nonvalvular AF in updated
treatment guidelines [19, 20].
Clinical Trials: Regulatory approval of dabigatran
etexilate for stroke prevention in AF is based on the find-
ings of the Randomized Evaluation of Long-term antico-
agulation therapY (RE-LY) trial (ClinicalTrials.gov record:
NCT00262600) [44]. RE-LY was a non-inferiority trial
comparing the long-term efficacy and safety of dabigatran
etexilate with warfarin for the prevention of stroke and
systemic embolism in patients with AF (Table 3) [44].
Dabigatran etexilate dosage was blinded, but warfarin
treatment was open-label. The primary efficacy endpoint
was the incidence of stroke or systemic embolism. Dabi-
gatran etexilate was non-inferior to warfarin in preventing
the primary endpoint in patients with AF, with comparable
or lower rates of major bleeding depending on the dose
[45]. Dabigatran etexilate 110 mg twice daily met the
predefined non-inferiority criteria versus warfarin, while
dabigatran etexilate 150 mg twice daily was superior to
warfarin (RR 0.66; 95 % CI 0.53–0.829). After a subse-
quent analysis of RE-LY looked at the association between
dabigatran and clinical/silent as well as other ischemic
myocardial events, there is debate as to whether the risk of
Table 3 Efficacy and safety studies of the direct oral anticoagulants in nonvalvular atrial fibrillation
Dabigatran RE-LY Rivaroxaban ROCKET-AF Apixaban ARISTOTLE Edoxaban ENGAGE AF
N:Randomized 18,113 14,264 18,201 21,105
Mean age (years old) 72 73 70 72
Female (%) 27 40 35 38
Paroxysmal AF (%) 32 18 15 25
VKA naive (%) 50 38 43 41
Aspirin use (%) 40 36 31 29
Median TTR (%) 66 58 66 68
Mean CHADS2 Score 2.1 3.5 2.1 2.8
Efficacy: RR (95% CI) 0.66 (0.53–0.82) 0.80 (0.75–1.3) 0.80 (0.67–0.95) 0.88 (0.75–1.02)
Safety: RR (95% CI) 0.93 (0.81–1.7) 1.03 (0.96–1.11) 0.69 (0.60–0.80) 0.80 (0.71–0.90)
Efficacy 150 mg: superior
110 mg: non-inferior
Non-inferior Superior Non-inferior
Safety 150 mg: non-inferior
110 mg: superior
Non-inferior Superior Superior
AF atrial fibrillation, CI confidence interval, RR relative risk, TTR time spent in therapeutic range, VKA vitamin K antagonist
176 L. Alcocer
heart attack is higher with dabigatran compared to warfarin
[46], When you look at the totality of benefits with dabi-
gatran–the reduction in hemorrhagic stroke [47], ischemic
stroke [48], and bleeding [49] vs the increased number of
MI–there is clearly a net clinical benefit in favor of dabi-
gatran over warfarin.
2.2.2 Rivaroxaban
Rivaroxaban (Xarelto; Bayer, Janssen) is a direct inhibitor
of factor Xa. Factor Xa is involved in the intrinsic and
extrinsic coagulation pathways and is responsible for the
conversion of prothrombin to thrombin [50, 51]. Consistent
with the observation that coagulation progresses in an
amplified manner, one molecule of factor Xa catalyzes the
formation of approximately 1000molecules of thrombin [52,
53]. Inhibition of factor Xa can effectively prevent both
platelet-rich arterial thrombi and fibrin-rich venous thrombi
[54]. Rivaroxaban has an oral bioavailability of 63–79 %and
a half-life of 7–13 h; only 36 % is excreted in urine as
unchanged drug. In addition, *two-thirds is excreted as
inactive metabolites and feces, although there are hepatic
drug interactions with strong P-gp and CYP3A4 inhibitors
and inducers, with the remainder being eliminated via the
liver [28]. Rivaroxaban is indicated for the prevention of
VTE in adults undergoing hip and knee replacement surgery,
for the short- and long-term treatment of patients with deep
vein thrombosis and pulmonary embolism, and for stroke
prevention in patients with nonvalvular AF [50]. It was
approved by COFEPRIS in Mexico for the prevention of
thromboembolic events in patients with nonvalvular AF in
March 2012, and in December 2012 for the secondary pre-
vention of ACS. The recommended dose of rivaroxaban for
stroke prevention inAF is 20 mgonce daily, which should be
administered with food [50]. In patients with moderate renal
impairment (CLCR\50–30mL/min) the recommended dose
of rivaroxaban is 15 mg once daily. The drug may be used
with caution in patients with severe renal impairment (CLCR
15–29 mL/min), and is contraindicated in those with end-
stage renal disease (ESRD) [CLCR\15 mL/min).
Clinical Trials: Evidence for the efficacy of rivaroxaban
in stroke prevention in AF comes from the Rivaroxaban
Once Daily Oral Direct Factor Xa Inhibitor Compared with
Vitamin K Antagonism for Prevention of Stroke and
Embolism Trial in Atrial Fibrillation (ROCKET-AF).
ROCKET-AF was a phase III, randomized, multicenter,
double-blind, active-controlled trial investigating the effi-
cacy of rivaroxaban versus warfarin in 14,264 patients with
nonvalvular AF who were at an increased risk of stroke
(ClinicalTrials.gov record: NCT00403767) [55]. Patients
were randomized to rivaroxaban 20 mg/day (or 15 mg/day
in patients with moderate renal impairment at screening) or
to dose-adjusted warfarin titrated to an INR of 2.5 [55].
The primary efficacy endpoint was the incidence of stroke
(hemorrhagic or ischemic) or systemic embolism. The
primary safety endpoint was the incidence of major and
clinically relevant non-major bleeding events. In the intent-
to-treat analysis, rivaroxaban was non-inferior to warfarin,
with a stroke/systemic embolism rate of 2.1 % per year in
the rivaroxaban arm versus 2.4 % per year in warfarin-
treated patients [hazard ratio (HR) 0.88; 95 % CI
0.75–1.03; p\ 0.001 for non-inferiority] [55]. The rates of
the primary safety endpoint were similar in the rivaroxaban
and warfarin arms (14.9 vs. 14.5 %; HR 1.03; 95 % CI
0.96–1.11; p = 0.44); however, the incidences of ICH and
fatal bleeding were significantly reduced with rivaroxaban
(0.5 vs. 0.7 %, p = 0.02, and 0.2 vs. 0.5 %, p = 0.003,
respectively). The efficacy and safety findings of
ROCKET-AF were consistent across pre-specified patient
subgroups, including patients with renal impairment, and
across TTR quartiles for the warfarin arm, in the intent-to-
treat analysis and not in the per-protocol analysis; the on-
treatment sub group analysis, which was pre-specified,
demonstrated superiority [55] (Table 3).
2.2.3 Apixaban
Like rivaroxaban, apixaban [Eliquis, Bristol Myers Squibb
and Pfizer (International), and Elicuis, Pfizer (Mexico)] is
an oral pyrazole-based direct factor Xa inhibitor. Apixaban
has an oral bioavailability of 66 % and a half-life of 8–15 h
[28]. Elimination of apixaban occurs via multiple routes. Of
the administered apixaban dose in humans, approximately
25 % was recovered as metabolites, with the majority
recovered in feces. Renal excretion of apixaban accounts for
approximately 27 % of total clearance. Additional contri-
butions from biliary and direct intestinal excretion were
observed in clinical and nonclinical studies, respectively.
Apixaban was approved for the prevention of stroke and
systemic embolism in patients with nonvalvular AF in
Mexico in 2013, in the European Union (EU) in November
2012, and in the USA in December 2012 [56, 57]; it is also
indicated in the EU for the prevention of VTE in adult
patients who have undergone elective hip or knee replace-
ment surgery [58]. In Mexico it was approved also for pre-
vention of VTE in adults undergoing hip and knee
replacement surgery, and for the short- and long-term
treatment of patients with deep vein thrombosis and pul-
monary embolism. The recommended dose of apixaban for
patients with AF is 5 mg twice daily, although a reduced
dose (2.5 mg twice daily) is recommended for patients with
two or more of the following characteristics: age C80 years,
bodyweight B60 kg, and serum creatinine C1.5 mg/dL.
No dose adjustment is recommended for patients with
renal impairment alone, including those with ESRD
maintained on hemodialysis, except nonvalvular AF
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patients who meet the criteria for dosage adjustment
defined in the previous paragraph [58].
Clinical Trials: Two phase III trials have investigated
the efficacy and tolerability of apixaban for stroke pre-
vention in patients with AF (Table 3) [59, 60]. The
multinational Apixaban for Reduction In STroke and Other
ThromboemboLic Events in Atrial Fibrillation (ARIS-
TOTLE) trial compared apixaban with warfarin (Clini-
calTrials.gov record: NCT00412984) [59]. The primary
efficacy endpoint was the incidence of stroke (hemorrhagic
or ischemic) or systemic embolism, and the primary safety
endpoint was major bleeding. ARISTOTLE demonstrated
that apixaban was more effective than warfarin in reducing
stroke, with the primary endpoint occurring at a rate of
1.27 % per year versus 1.51 % per year in the warfarin
group; the between-group difference met predefined supe-
riority criteria (Table 3) [59]. The incidence of major
bleeding events and the rate of ICH and death were also
significantly lower with apixaban versus warfarin (both
p\ 0.001). Secondary analysis of the ARISTOTLE results
showed no evidence of differential benefits of apixaban
versus warfarin in different stroke or bleeding risk cate-
gories [61] and that apixaban demonstrated consistent
effects in patients with a previous stroke or TIA and those
without. The Apixaban Versus Acetylsalicylic Acid to
Prevent Stroke in Atrial Fibrillation in Patients Who Have
Failed or Are Unsuitable for Vitamin K Antagonist
Treatment (AVERROES) trial was designed to determine
whether apixaban was superior to aspirin for preventing the
composite outcome of stroke or systemic embolism in
patients with AF and at least one additional risk factor for
whom VKA therapy was considered unsuitable (Clini-
calTrials.gov record: NCT00496769) [62]. Patients were
randomized to apixaban or aspirin, and the primary efficacy
endpoint was the incidence of stroke or systemic embolism.
AVERROES was intended to follow patients for a treat-
ment period of up to 36 months; however, the trial was
ended early after an interim analysis by the Data and Safety
Monitoring Committee determined that apixaban demon-
strated overwhelmingly superior efficacy compared with
aspirin. The primary endpoint occurred at rates of 1.6 and
3.7 % per year in patients receiving apixaban and aspirin,
respectively; the between-group difference met predefined
superiority criteria (Table 3). Rates of major bleeding, the
primary safety endpoint, were similar in the apixaban and
aspirin groups, and consistency in treatment effects was
seen across patient subgroups. As seen in the other novel
anticoagulant studies, patients with prior stroke or TIA had
higher incidences of stroke or systemic embolism than
those without, regardless of which treatment arm they had
been assigned to [62]. However, the incidence was sig-
nificantly reduced with apixaban compared with aspirin in
both subgroups (major bleeding also occurred more
frequently in patients with a previous stroke or TIA than
those without, but no significant difference was seen
between apixaban and aspirin in either subgroup)
(Table 3).
2.2.4 Edoxaban
Edoxaban is a new DOAC, not available in Mexico [63],
whose mechanism of action involves direct and reversible
inhibition of factor Xa. It has a 62 % bioavailability with a
half-life (terminal) of 10–14 h. It is metabolized minimally
by hydrolysis conjugation and CYP3A4-mediated oxida-
tion. It is excreted 50 % unchanged in urine; because of its
high renal clearance, blood levels of edoxaban are higher in
patients with impaired renal function. Systemic exposure to
edoxaban was[70 % higher among patients with a CLCR
of B50 mL/min than among those with a CLCR of[80 mL/
min.
Clinical Trials: Edoxaban versus warfarin in patients
with atrial fibrillation trial (ENGAGE AF-TIMI 48) [64] is
a randomized, double-blind trial comparing two once-daily
regimens of edoxaban with warfarin in 21,105 patients with
AF and a CHADS2 score of 2, with a median follow-up to
2.8 years. Each edoxaban regimen was tested for non
inferiority to warfarin. The principal safety endpoint was
major bleeding. Both once-daily regimens of edoxaban
were non-inferior to warfarin with respect to the prevention
of stroke or systemic embolism and were associated with
significantly lower rates of bleeding and death from car-
diovascular causes. Comparing both edoxaban doses, the
high dose has greater efficacy in the prevention of ischemic
events, particularly ischemic stroke, at the cost of more
bleeding, including intracranial hemorrhage, however
hemorrhagic strokes and CV mortality were both signifi-
cantly lower on both edoxaban regimens than on warfarin.
There is a balance between the efficacy and safety of the
two doses; no differences between the two doses in overall
mortality and cardiovascular mortality were observed. The
primary endpoint (stroke or systemic embolism) occurred
after a median follow-up of 2.8 years at a significantly
lower annual rate with edoxaban than with warfarin (1.18
vs. 1.50 %). Edoxaban use was also associated with sig-
nificantly reduced annual rates of major bleeding (2.75 vs.
3.43 %), intracranial bleeding (0.39 vs. 0.85 %), and car-
diovascular death (2.74 vs. 3.17 %). Among patients with a
CLCR of [95 mL/min, the rate of ischemic stroke was
significantly higher with edoxaban (0.9 %) than with
warfarin (0.4 %) [65] (Table 3).
2.3 Indirect Comparisons of the DOACs
With the approval of apixaban in Mexico in April 2013 by
the Mexican Drug Agency (COFEPRIS [Comisio´n Federal
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para la Proteccio´n contra Riesgos Sanitarios]), and with
dabigatran and rivaroxaban already available, clinicians in
Mexico have the same choice of three novel oral antico-
agulants for stroke prevention in AF as those in the USA
and Europe. It is therefore important that certain questions
are answered in the near future. The first question is
whether the novel oral anticoagulants should replace war-
farin. A recent meta-analysis of data from four DOACs,
studied for the prevention of stroke or systemic embolic
events in patients with AF not valvular, showed that oral
direct anticoagulants had a favorable benefit–risk profile,
with significant reductions in stroke, ICH, and mortality
and severe bleeding similar to warfarin, but increased
gastrointestinal bleeding [66]. The most important advan-
tage with the use of any of the three novel oral anticoag-
ulants is that they are associated with reduced rates of ICH
compared with warfarin, as ICH is arguably the most
feared complication of oral anticoagulant therapy [67]. The
main limitation of the novel oral anticoagulants is that none
has been followed for a long time, whereas VKAs have
been in use for[50 years and there is a large amount of
clinical data on their long-term use.
Another key question that arises is which of the three
novel anticoagulants should be the first choice. Several
pooled analyses have not been able to provide a consensus
on this [68–71], and there have been no head-to-head
clinical trials of these agents in patients with AF; however,
differences in their pharmacokinetic and pharmacodynamic
properties and data from clinical trials may help determine
which treatment is best suited to particular patients [72]
(Fig. 1).
There is currently a lack of specific data on the effects of
the DOACs in Mexican or Hispanic patients in phase III
trials; therefore, treatment decisions must be based on
effects in the overall patient population. Nevertheless, it
should be noted that the Mexican population was indeed
included in both of the pivotal apixaban trials and in studies
of dabigatran and rivaroxaban; while a specific sub-anal-
ysis of these global population studies in Mexican patients
cannot be conducted as they were not powered for sub-
population analyses, these direct anticoagulants were
effective in these patients. Although dabigatran, rivaroxa-
ban, and apixaban all showed reductions in ICH versus
warfarin in phase III studies, dabigatran 150 mg twice
daily was the only drug that reduced the risk of cerebral
infarction over warfarin. Dabigatran and apixaban were the
only ones to show a significant reduction in stroke/systemic
embolism, and only apixaban significantly reduced mor-
tality and major bleeding [45, 55, 59]. Both dabigatran and
rivaroxaban were associated with significantly increased
gastrointestinal bleeding versus warfarin, but apixaban was
not. Apixaban and rivaroxaban are less dependent on renal
elimination than dabigatran, and appear to be less likely to
be associated with gastrointestinal adverse events [45, 55,
59]. The 2014 American Heart Association/American
Stroke Association (AHA/ASA) ‘‘Guidelines for the
Prevention of Stroke in Patients With Stroke and Transient
Ischemic Attack’’ recommend VKA therapy (class I; level
of evidence A), apixaban (class I; level of evidence A), and
dabigatran (class I; level of evidence B) for the prevention
of recurrent stroke in patients with nonvalvular AF, whe-
ther paroxysmal or permanent [73]. Updated guidelines
from the American College of Chest Physicians recom-
mend dabigatran 150 mg twice daily rather than VKAs
(grade 2B), but do not make recommendations regarding
the use of apixaban or rivaroxaban as they were not
approved at the time of drafting the guidelines [20]. The
most recent European Society of Cardiology (ESC)
guidelines recommend the use of these DOACs (a direct
thrombin inhibitor or a factor Xa inhibitor) when VKAs
cannot be used because of difficulties in keeping within
therapeutic anticoagulation, an inability to attend or
undertake INR monitoring or the occurrence of adverse
events with VKAs (class IB) [18]. When oral anticoagu-
lants are recommended, either a direct thrombin inhibitor
or a factor Xa inhibitor should be considered rather than a
VKA, as in most patients with nonvalvular AF, based on
their net clinical benefit (class IIa, level A) [18] (Fig. 1).
The management of anticoagulated patients undergoing
surgery is a common clinical problem; AF accounts for the
largest percentage of this particular clinical situation.
Surgical or other invasive procedures were required in a
quarter of patients in RE-LY and a third of patients in
ROCKET-AF and ARISTOTLE. Of the 4591 patients
underwent at least 1 invasive procedure in the RE-LY trial,
the perioperative thromboembolic risk was 1.2 %, based on
a combined endpoint of stroke, cardiovascular death, and
pulmonary embolism [74]. There were no differences in
thromboembolic risk with dabigatran compared with war-
farin or high- versus low-dose dabigatran. However, urgent
surgery was associated with an increased risk of ischemic
stroke or systemic embolism (warfarin 1.8 vs. 0.4 %;
dabigatran 150 mg twice daily 1.4 vs. 0.4 %; dabigatran
110 mg twice daily 2.8 vs. 0.3 %). Of the 4692 ROCKET
anticoagulant interruptions, 40 % were for surgery or
invasive procedures [65]. Thromboembolic risk during
anticoagulant interruption was similar to that for rivarox-
aban and warfarin (0.3 and 0.4 %). During 9260 proce-
dures performed on patients in the ARISTOTLE trial,
perioperative thromboembolic risk was 0.57 % for war-
farin and 0.35 % for apixaban [75]. Two of these trials
showed that treatment absolutely must not combine
LMWH/UFH/fondaparinux with NOACs. In Mexico, local
guidelines regarding stroke prevention in AF are very
basic. Two guidelines are available, one relating to the
management of anticoagulants and the other the
SPAF in Mexico 179
management of AF in primary care [76, 77]. These
guidelines do not discuss the use of novel oral anticoagu-
lants in patients with AF and are thus not suitable for the
current clinical situation. Thus, we can assume that Mex-
ican physicians will rely on their own clinical judgment
and international guidelines to inform their prescribing
decisions until local Mexican guidelines are updated.
3 Conclusions
Patients with AF generally have an increased risk of stroke.
While warfarin is very effective at reducing stroke risk in
these patients, it has several significant disadvantages,
including the need for regular coagulation monitoring and
dose adjustment and a large number of interactions with
other medications and with certain foods. Several direct
anticoagulants have recently become available that cir-
cumvent the issues seen with warfarin, and while there is
not yet the wealth of data from clinical trials and the use of
these agents in clinical practice that there is for warfarin,
the data thus far for these agents in the prevention of stroke
in AF have been promising. AF and its complications (such
as stroke) are a growing problem in Mexico, which can be
explained in particular by the increasing population aged
over 65 years. Prevention of thromboembolic complica-
tions of AF using anticoagulants is a very effective and
cost-effective strategy. The VKAs have been used suc-
cessfully for many years and have been shown to signifi-
cantly decrease stroke risk in patients with nonvalvular AF;
however, their subsequent management is complex. Health
services in the Mexican public sector are staggered, so that
the first level medical health provider is one who should
diagnose the presence of AF and refer the patient to the
second or third level of provider for anticoagulant pre-
scribing and management. Ideally, the long-term manage-
ment of anticoagulants should be monitored in the first
level of health care; however, the complexity of traditional
anticoagulant management has made it necessary for their
prescription and management to occur in specialized cen-
ters such as anticoagulation clinics. Such centers are
complex and expensive to establish and maintain, and in
Mexico, they are often overwhelmed by a huge demand.
While popular belief is that the DOACs are very expensive,
they in fact represent a niche opportunity for optimization
of limited health resources, particularly for the prevention
of stroke in AF. The DOACs have been broadly used in
Mexico since 2008, and have demonstrated at least com-
parable effectiveness to that of VKAs, with superior safety
and simpler management. These agents may represent an
opportunity for long-term management to be undertaken by
the primary care physician once the drug is prescribed by
the specialist. The diagnosis of AF, communicating the
need for the lifetime use of anticoagulants to prevent stroke
and other complications, and the proper handling of anti-
coagulants all require continuous medical education,
directed not only to the specialist but also to the general
practitioner.
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